| Trial ID: | L0107 |
| Source ID: | NCT02726542
|
| Associated Drug: |
Somatropin
|
| Title: |
Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents
|
| Acronym: |
--
|
| Status: |
Completed
|
| Study Results: |
Has Results
|
| Results: |
https://ClinicalTrials.gov/show/NCT02726542/results
|
| Conditions: |
NAFLD
|
| Interventions: |
Drug: somatropin
|
| Outcome Measures: |
Change in Hepatic Fat Fraction|Change in Aspartate Aminotransferase (AST)|Change in Alanine Aminotransferase (ALT)|Change in Gamma Glutamyl Transferase|Change in Visceral Adipose Tissue
|
| Sponsor/Collaborators: |
Massachusetts General Hospital
|
| Gender: |
All
|
| Age: |
18 Years to 29 Years ?? (Adult)
|
| Phases: |
Early Phase 1
|
| Enrollment: |
24
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
|
| Start Date: |
May 3, 2017
|
| Completion Date: |
April 2, 2020
|
| Results First Posted: |
April 26, 2021
|
| Last Update Posted: |
April 26, 2021
|
| Locations: |
Massachusetts General Hospital, Boston, Massachusetts, United States
|
| URL: |
https://ClinicalTrials.gov/show/NCT02726542
|
